Breakthrough in treatment of blindness caused by Retinitis Pigmentosa

64% of patients treated with Bone Marrow Stem Cells show improved vision in new key report

Retinitis Pigmentosa or RP is a progressive, blinding eye disease that typically affects younger people and robs them of their vision.  It is hereditary meaning that a parent may have a child and sadly watch the vision loss develop or a younger sibling may see an older one losing vision and know the same fate awaits them.  Until now there has been no treatment to help reverse the vision loss. Now for the first time a group of research physicians using stem cells from the persons own bone marrow has reported success in improving vision for patients with RP.  

MD Stem Cells and The Healing Institute have been collaborating for several years in the largest Institutional Review Board approved stem cell studies in ophthalmology called the Stem Cell Ophthalmology Treatment Study or SCOTS and SCOTS 2.  Their success developing stem cells for otherwise untreatable retinal and optic nerve disease has angered organizations and blogs aligned with the pharmaceutical industry.  Misleading press reports have attempted to confuse their efforts with stem cell clinics that have no research focus.  Despite the naysayers, and with quiet support from referring clinicians and their many patients with positive outcomes, their researchers have persisted and steadily developed their successful approach.  Now in their breakthrough peer-reviewed paper Stem Cell Ophthalmology Treatment Study: bone marrow derived stem cells in the treatment of Retinitis Pigmentosa, they have shown improved vision for RP is now possible. 

In the paper 64.7% of patients showed improved vision using both eyes averaging 10.23 lines of Snellen vision (the eye chart used in most eye doctors offices) after the SCOTS treatment.  45.5% of individual eyes improved and 45.5% showed stable vision instead of worsening.  A research vision measurement called logMAR showed 40.9% improvement over baseline vision in improved eyes. The results were statistically significant which is the gold standard in medicine for determining if a treatment works. For access to the paper see

The SCOTS approach is to use autologous- meaning from the same person- bone marrow stem cells (BMSC).  Because the stem cells come from the same person there can be no rejection.  The bone marrow stem cells are quite different from fat or adipose stem cells which have been reported to cause harm to the eye.  SCOTS and now SCOTS 2 have been ongoing for almost 5 years with over 500 patients treated- so there is a vast amount of experience and technology using bone marrow stem cells that has been developed specifically for the eyes.  SCOTS 2 is continuing to enroll and treat patients.

We are gratified to know our hard work developing this approach has been proven to be of benefit to patients with Retinitis Pigmentosa and continues to be available through our study indicated Dr. Levy, CEO of MD Stem Cells and Study Director for SCOTS and SCOTS 2.  Patients and eye care providers should know our approach is the first treatment shown to potentially improve vision for patients with RP.  The improvements in vision are statistically significant and the safety profile for the procedure is excellent. This is a huge breakthrough in ophthalmology and for regenerative medicine.  I wish to thank all the patients who provided the needed follow-up allowing for reporting of these results

The Stem Cell Ophthalmology Study II (SCOTS 2) is a patient sponsored study which means there are direct costs to the patient for treatment.  Patients can find the study on the National Institutes of Health listing called under NCT 03011541.  Visual improvement statistics and data shown apply to this group of patients as a whole – individual patient results cannot be predicted.  Patients interested in participating in the SCOTS 2 study may email Dr. Levy at for more information.  He may also be reached at 203-423-9494 or through the website 

Media Contact
Company Name: Release News
Contact Person: Andrew Braithwaite
Email: Send Email
Phone: +44 (0) 161 818 6487
Country: United States